Baird Raises Price Target on Innoviva (INVA) as GSK Announces Strong Sales

July 28, 2016 8:10 AM

Baird reiterated a Neutral rating on Innoviva (NASDAQ: INVA), and raised the price target to $11.00 (from $9.00), after GSK ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found